My research focuses on flaviviruses and coronaviruses. The overall aim is to use a genetic approach to study the molecular basis of viral RNA replication/assembly, virulence, pathogenesis, and host/viral interactions. My research generates critical tools and platforms for translation applications , including antiviral, vaccine, and diagnostics development. I pioneered the development of a preclinical NS4B inhibitor against dengue virus and co-developed the reverse genetic system of ZIKV and the live-attenuated ZIKV vaccine candidate with a 3’UTR Δ10 deletion. During the COVID-19 pandemic, I developed the first peer-reviewed reverse genetic system of SARS-CoV-2 and high-throughput platforms for screening antiviral and neutralizing antibodies. I am co-leading the UTMB-Novartis Alliance for Pandemic Preparedness (UNAPP) interdisciplinary team on drug discovery for flaviviruses, coronaviruses, and henipavirus for future pandemic preparedness. I have established extensive collaborations with a multidisciplinary team at UTMB including Drs. Vineet Menachery, Scott Weaver, Tina Wang, Jia Zhou, and Alexander Freiberg.